Abbott Laboratories (NYSE:ABT) Stock Sale Reported by Rep. Pete Sessions

Key Points

• Rep. Pete Sessions sold $50,001–$100,000 of Abbott Laboratories stock from his “TRUST ONE” account on October 2, with the transaction disclosed on October 27. He also reported selling shares of several other companies in October.
• Abbott reported quarterly revenue of $13.01 billion, up 14.5% year over year, while earnings of $1.42 per share matched analyst expectations. The company declared a quarterly dividend of $0.63 per share, representing a 2.5% yield.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $118.32 target price, although Argus downgraded the stock to “Hold.” Abbott is also expanding its diagnostics business, planning a Nutrition segment spin-off and benefiting from continued institutional ownership.

Representative Pete Sessions (Republican-Texas) recently sold shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on October 27th, the Representative disclosed that they had sold between $50,001 and $100,000 in Abbott Laboratories stock on October 2nd. The trade occurred in the Representative's "TRUST ONE" account.

Representative Pete Sessions also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Walt Disney NYSE: DIS on 10/28/2026.
• Sold $15,001 - $50,000 in shares of Amazon.com NASDAQ: AMZN on 10/27/2026.
• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 10/27/2026.
• Sold $15,001 - $50,000 in shares of Lowe's Companies NYSE: LOW on 10/22/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 10/22/2026.
• Sold $1,001 - $15,000 in shares of Solstice Advanced Mat NASDAQ: SOLS on 10/21/2026.
• Sold $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 10/21/2026.
• Sold $0 - $1,000 in shares of Resideo Technologies NYSE: REZI on 10/21/2026.
• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 10/20/2026.
• Sold $15,001 - $50,000 in shares of Berkshire Hathaway NYSE: BRK.B on 10/15/2026.

Abbott Laboratories Price Performance

NYSE ABT opened at $102.66 on Thursday. The company has a 50-day moving average price of $104.72 and a two-hundred day moving average price of $102.26. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02. The stock has a market cap of $177.64 billion, a price-to-earnings ratio of 38.31, a price-to-earnings-growth ratio of 1.82 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts' consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The company had revenue of $13.01 billion for the quarter, compared to analysts' expectations of $12.99 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The business's revenue for the quarter was up 14.5% compared to the same quarter last year. Analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's payout ratio is presently 94.03%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Argus cut Abbott Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday. Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $119.00 to $127.00 in a research report on Friday, October 2nd. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an "overweight" rating in a report on Thursday, October 22nd. Finally, Citigroup reduced their price objective on shares of Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating for the company in a research report on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $118.32.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp lifted its holdings in shares of Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after buying an additional 1,350,766 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $1,603,607,000. Deutsche Bank AG boosted its position in shares of Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock valued at $1,515,963,000 after acquiring an additional 2,614,965 shares during the period. Finally, Legal & General Group Plc acquired a new stake in shares of Abbott Laboratories in the second quarter worth $1,082,524,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott launched a next-generation Oncodetect test designed to detect residual cancer disease, expanding its diagnostics portfolio and potentially supporting longer-term growth in oncology testing. Abbott Launches Next-Generation Oncodetect Test
• Positive Sentiment: The planned spin-off of Abbott’s Nutrition segment, which generates approximately $8.5 billion in annual sales, could allow the remaining company and the new standalone business to pursue more focused strategies. Abbott has appointed Daniel Salvadori to lead the future Nutrition company. What Could Abbott Laboratories Spin Off Mean for Its Future Growth?
• Positive Sentiment: Abbott received approximately $23.9 million in net ETF buying, indicating some continued institutional demand for ABT shares despite recent volatility. Abbott Sees $23.9 Million in Net ETF Buying
• Neutral Sentiment: Abbott is included in coverage of Europe’s medical foods market, which is projected to grow from $6.5 billion in 2026 to $7.9 billion by 2033. The outlook highlights a long-term opportunity for Abbott’s specialized nutrition business, though it does not represent new company-specific revenue. Europe Medical Foods Market Strategic Outlook
• Negative Sentiment: Argus Research downgraded Abbott from “Buy” to “Hold,” reportedly citing a guidance cut. The change removes a bullish rating catalyst and reinforces investor concerns about near-term demand and earnings visibility. Abbott Downgraded at Argus on Guidance Cut
• Negative Sentiment: Higher interest-rate expectations are creating pressure on richly valued quality-growth stocks such as Abbott, as elevated rates can reduce the value investors assign to future earnings. Demand headwinds and litigation risks are also cited as concerns. Abbott Demand Headwinds and Litigation Risks

About Representative Sessions

Pete Sessions (Republican Party) is a member of the U.S. House, representing Texas' 17th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Sessions (Republican Party) ran for re-election to the U.S. House to represent Texas' 17th Congressional District. He won in the general election on November 5, 2024. On October 20, 2023, Sessions announced he was running to replace Kevin McCarthy (R) as speaker of the U.S. House in the 118th Congress. Sessions lost the first round of nomination voting on October 24, 2023. Pete Sessions was born and lives in Waco, Texas. Sessions earned a B.S. from Southwestern University in 1978. Sessions' career experience includes working as an executive with AT&T.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.